Kunming Longjin Pharmaceutical Co Ltd
Kunming Longjin Pharmaceutical Co., Ltd. therapeutic medicines for people living with cardiovascular, cerebrovascular, and metabolic diseases in China. The company offers medicines in the areas of cardiovascular and cerebrovascular, digestive system, vitamin, minerals and enteral nutrition, and immunology, as well as first aid kits; extracts of natural plants, such as breviscapine; and industrial… Read more
Kunming Longjin Pharmaceutical Co Ltd (002750) - Net Assets
Latest net assets as of March 2025: CN¥485.19 Million CNY
Based on the latest financial reports, Kunming Longjin Pharmaceutical Co Ltd (002750) has net assets worth CN¥485.19 Million CNY as of March 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥555.15 Million) and total liabilities (CN¥69.96 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥485.19 Million |
| % of Total Assets | 87.4% |
| Annual Growth Rate | 7.77% |
| 5-Year Change | -29.87% |
| 10-Year Change | -17.55% |
| Growth Volatility | 31.15 |
Kunming Longjin Pharmaceutical Co Ltd - Net Assets Trend (2011–2024)
This chart illustrates how Kunming Longjin Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Kunming Longjin Pharmaceutical Co Ltd (2011–2024)
The table below shows the annual net assets of Kunming Longjin Pharmaceutical Co Ltd from 2011 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥494.21 Million | -8.67% |
| 2023-12-31 | CN¥541.13 Million | -10.52% |
| 2022-12-31 | CN¥604.77 Million | -10.84% |
| 2021-12-31 | CN¥678.29 Million | -3.75% |
| 2020-12-31 | CN¥704.71 Million | +5.83% |
| 2019-12-31 | CN¥665.89 Million | +1.52% |
| 2018-12-31 | CN¥655.93 Million | +1.61% |
| 2017-12-31 | CN¥645.54 Million | -3.72% |
| 2016-12-31 | CN¥670.46 Million | +11.85% |
| 2015-12-31 | CN¥599.41 Million | +109.90% |
| 2014-12-31 | CN¥285.57 Million | -5.44% |
| 2013-12-31 | CN¥302.00 Million | +33.07% |
| 2012-12-31 | CN¥226.94 Million | +21.53% |
| 2011-12-31 | CN¥186.74 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Kunming Longjin Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 82.7% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥18.95 Million | 4.03% |
| Other Components | CN¥451.51 Million | 95.97% |
| Total Equity | CN¥470.46 Million | 100.00% |
Kunming Longjin Pharmaceutical Co Ltd Competitors by Market Cap
The table below lists competitors of Kunming Longjin Pharmaceutical Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PT Black Diamond Resources Tbk
JK:COAL
|
$12.10 Million |
|
Hyprop
JSE:HYP
|
$12.10 Million |
|
Lippo Cikarang Tbk
JK:LPCK
|
$12.11 Million |
|
Riverview Rubber Estates Bhd
KLSE:2542
|
$12.11 Million |
|
Queen City Investments Inc
PINK:QUCT
|
$12.09 Million |
|
Air Industries Group
NYSE MKT:AIRI
|
$12.09 Million |
|
Gumho NT Co Ltd
KQ:130500
|
$12.09 Million |
|
Partner Tech Corp.
TWO:3097
|
$12.08 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Kunming Longjin Pharmaceutical Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 511,886,948 to 470,459,143, a change of -41,427,805 (-8.1%).
- Net loss of 41,443,575 reduced equity.
- Dividend payments of 168,459 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥-41.44 Million | -8.81% |
| Dividends Paid | CN¥168.46K | -0.04% |
| Other Changes | CN¥184.23K | +0.04% |
| Total Change | CN¥- | -8.09% |
Book Value vs Market Value Analysis
This analysis compares Kunming Longjin Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.50x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.37x to 0.50x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | CN¥1.61 | CN¥0.59 | x |
| 2018-12-31 | CN¥1.62 | CN¥0.59 | x |
| 2019-12-31 | CN¥1.56 | CN¥0.59 | x |
| 2020-12-31 | CN¥1.59 | CN¥0.59 | x |
| 2021-12-31 | CN¥1.60 | CN¥0.59 | x |
| 2022-12-31 | CN¥1.46 | CN¥0.59 | x |
| 2023-12-31 | CN¥1.28 | CN¥0.59 | x |
| 2024-12-31 | CN¥1.17 | CN¥0.59 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Kunming Longjin Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.81%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -62.34%
- • Asset Turnover: 0.12x
- • Equity Multiplier: 1.22x
- Recent ROE (-8.81%) is below the historical average (9.03%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2011 | 37.30% | 46.89% | 0.52x | 1.54x | CN¥50.99 Million |
| 2012 | 44.15% | 55.01% | 0.49x | 1.62x | CN¥77.51 Million |
| 2013 | 24.85% | 41.97% | 0.40x | 1.47x | CN¥44.86 Million |
| 2014 | 22.26% | 33.92% | 0.43x | 1.53x | CN¥35.02 Million |
| 2015 | 10.31% | 34.06% | 0.26x | 1.17x | CN¥1.86 Million |
| 2016 | 13.58% | 40.71% | 0.29x | 1.13x | CN¥23.99 Million |
| 2017 | 5.45% | 11.55% | 0.39x | 1.22x | CN¥-29.39 Million |
| 2018 | 2.14% | 4.13% | 0.43x | 1.22x | CN¥-50.87 Million |
| 2019 | -3.70% | -8.39% | 0.34x | 1.29x | CN¥-85.53 Million |
| 2020 | 1.86% | 4.65% | 0.30x | 1.32x | CN¥-51.79 Million |
| 2021 | 0.48% | 0.44% | 0.85x | 1.29x | CN¥-60.82 Million |
| 2022 | -9.62% | -45.64% | 0.16x | 1.28x | CN¥-114.42 Million |
| 2023 | -13.86% | -81.90% | 0.14x | 1.23x | CN¥-122.13 Million |
| 2024 | -8.81% | -62.34% | 0.12x | 1.22x | CN¥-88.49 Million |
Industry Comparison
This section compares Kunming Longjin Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $2,123,990,643
- Average return on equity (ROE) among peers: -0.22%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Kunming Longjin Pharmaceutical Co Ltd (002750) | CN¥485.19 Million | 37.30% | 0.14x | $12.09 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.88% | 3.77x | $616.08 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $1.18 Billion | 2.74% | 0.95x | $320.56 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.33 Billion | 15.07% | 0.27x | $3.03 Billion |
| Wedge Industrial Co Ltd (000534) | $298.72 Million | 1.96% | 0.38x | $1.77 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $5.62 Billion |
| Hainan Haiyao Co Ltd (000566) | $353.98 Million | -9.58% | 0.80x | $702.18 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $269.51 Million | -61.02% | 1.05x | $317.08 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $927.49 Million | 2.65% | 1.38x | $425.60 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.11 Billion | 7.32% | 0.29x | $2.05 Billion |
| Renhe Pharmacy Co Ltd (000650) | $261.49 Million | 10.60% | 0.82x | $777.45 Million |